This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
akt
AKT
PI3K-AKT-mTOR pathway kinase; PIP3-activated by PDK1 and mTORC2 downstream of PIK3CA. Phosphorylates BAD/FOXO/MDM2 to promote survival and activates mTORC1 for growth. Capivasertib (pan-AKT inhibitor) approved 2023 for PIK3CA/AKT/PTEN-altered HR+/HER2- breast cancer.
Entry Metadata
| Field | Value |
|---|---|
| ID | akt |
| Name | AKT |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991;254(5029):274-277. · PubMed 1833819
- Manning BD, Cantley LC. AKT/PKB Signaling: Navigating Downstream. Cell. 2007;129(7):1261-1274. · PubMed 17604717
- Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-2070. · PubMed 37256976